Bionano Genomics, Inc. (Nasdaq: BNGO) today announced highlights from Day 3 of Bionano Symposium 2026, entitled OGM Making its Mark in Constitutional Genetic Disorders. Presentations highlighted how ...
The FDA approved Cleveland Diagnostics' blood-based test to help diagnose high-grade prostate tumors and aid in biopsy decisions, the company announced. Dubbed IsoPSA, the in vitro diagnostic kit is ...
You are currently accessing National Journal from IP access. Please login to access this feature. If you have any questions, please contact your Dedicated Advisor.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results